Latest news
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
Manufacturing expansion in the United States
Novartis is expanding our manufacturing and R&D facilities in the US to scale innovation, help patients and create jobs.
Bringing breakthroughs to more patients
At Novartis, we don’t just discover life-changing medicines, we're part of a broader effort to help ensure medicines reach the people who need them most, wherever they live, because the true value of innovation lies in its ability to improve lives.
Annual reporting suite
Explore and download our Annual Report 2025, Report on Nonfinancial Matters 2025 and other reporting documents.